ProCE Banner Activity

Should You Use IgHV Mutation Status to Select Optimal Choice of Therapy for Your Patients With CLL?

Clinical Thought
How I incorporate IgHV mutations status in my current clinical practice.

Released: November 16, 2016

Expiration: November 15, 2017

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Genentech Roche Virology

Janssen Pharmacyclics

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Celgene, Genentech, Gilead Sciences, and Pharmacyclics and funds for research support from AbbVie, Acerta, Celgene, Genentech, Gilead Sciences, and Pharmacyclics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Celgene, Genentech, Gilead Sciences, and Pharmacyclics and funds for research support from AbbVie, Acerta, Celgene, Genentech, Gilead Sciences, and Pharmacyclics.